News Releases
Filter by Year
November 22, 2022
LexaGene announces the completion of a validation study with a major biopharma company that recently purchased a MiQLab System for the possible use of the technology in its manufacturing processes.

November 1, 2022
LexaGene announces that it it has issued a 12% secured convertible note (the “Note”) to Meridian LGH Holdings 2, LLC.

October 27, 2022
LexaGene announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on October 29, 2019.

October 20, 2022
LexaGene announces that it has signed a statement of work with the same biopharma company that purchased a System last week.

October 13, 2022
LexaGene announces that it has received an indication that a major biopharma company intends to purchase its technology.

September 1, 2022
LexaGene announces that it has entered into a purchase agreement with a veterinary hospital in southern California.

August 29, 2022
LexaGene announces the MiQLab® System can perform the Centers for Disease Control and Prevention (CDC) Monkeypox real-time PCR test.

August 24, 2022
LexaGene has successfully configured the MiQLab System to use isothermal chemistry for individual pathogen detection in as soon as 30 minutes.

August 17, 2022
LexaGene announces the start of an evaluation of a gastrointestinal (GI) pathogen panel.

August 10, 2022
LexaGene has shortened the time the MiQLab® System needs to report a result by ~35%.

1 2 3 16

For Marketing inquiries, please email:

info@lexagene.com

800-215-1824